Eli Lilly and Company (NYSE:LLY) Receives Average Rating of “Moderate Buy” from Brokerages

Eli Lilly and Company (NYSE:LLY) has been assigned a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $728.05.

Several brokerages have recently weighed in on LLY. Barclays boosted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research report on Monday, April 15th. Finally, DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research report on Wednesday, February 21st.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently made changes to their positions in the business. Norges Bank purchased a new position in Eli Lilly and Company during the fourth quarter worth about $5,992,890,000. International Assets Investment Management LLC raised its holdings in Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Sapient Capital LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $682,139,000. J.P. Morgan Private Wealth Advisors LLC purchased a new position in Eli Lilly and Company in the third quarter valued at about $435,736,000. Finally, Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after buying an additional 659,838 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $724.87 on Friday. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a twelve month low of $370.68 and a twelve month high of $800.78. The business has a 50-day moving average price of $762.75 and a 200 day moving average price of $664.94. The firm has a market cap of $688.74 billion, a PE ratio of 124.98, a P/E/G ratio of 1.63 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the previous year, the firm posted $2.09 EPS. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. Sell-side analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.